Michael Wyand
Director Ejecutivo en Oxeia Biopharmaceuticals, Inc. .
Cargos activos de Michael Wyand
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Director/Miembro de la Junta | 06/09/2017 | - |
Director Ejecutivo | 06/09/2017 | - | |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Director/Miembro de la Junta | - | - |
Director Ejecutivo | - | - |
Historial de carrera de Michael Wyand
Antiguos cargos conocidos de Michael Wyand.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
EPIRUS BIOPHARMACEUTICALS, INC. | Director de Operaciones | 06/05/2016 | 30/06/2016 |
Director Técnico/Científico/I+D | 01/01/2012 | 06/05/2016 | |
Consejero General | 01/01/2012 | - | |
Presidente | 06/05/2016 | 30/06/2016 | |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Director Técnico/Científico/I+D | 07/05/2014 | - |
Consejero General | 07/05/2014 | - |
Formación de Michael Wyand.
Purdue University | Doctorate Degree |
University of Connecticut | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
General Counsel | 2 |
Director/Board Member | 2 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Health Technology |
Onebiopharma, Inc.
Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Services |
- Bolsa de valores
- Insiders
- Michael Wyand
- Experiencia